Company: XERI
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001477932-25-008494
Chunk: 41

Company: XERIANT, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
  5,772,263   8,765,577          Lease liability, long-term  1,965   3,105 Total liabilities  5,774,228   8,768,682          Commitments and contingencies (Note 9)                 Stockholders' deficit        Series A Preferred stock, $0.00001 par value; 100,000,000 authorized; 3,500,000 designated; 649,996 and 664,996 shares issued and outstanding at September 30, 2025, and June 30, 2025, respectively  7   7 Series B Preferred stock, $0.00001 par value; 100,000,000 authorized; 1,000,000 designated; 1,000,000 issued and outstanding  10   10 Common stock, $0.00001 par value; 5,000,000,000 shares authorized; 749,053,035 and 695,746,625 shares issued and outstanding at September 30, 2025, and June 30, 2025, respectively  7,492   6,958 Common stock to be issued  397,900   97,900 Additional paid in capital  22,881,775   22,410,416 Accumulated deficit  (26,112,534)  (28,338,606)Total stockholders' deficit  (2,825,350)  (5,823,315)Non-controlling interest  (2,877,148)  (2,877,148)Total stockholders' deficit  (5,702,498)  (8,700,463)Total liabilities and stockholders' deficit $71,730  $68,219 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 F-2Table of Contents

XERIANT, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 

UNAUDITED 

  For the three months ended   September 30,   2025  2024 Operating expenses:      Consulting and advisory fees $67,200  $88,983 Related party consulting fees  74,000   123,000 General and administrative expenses